June 2015
Volume 56, Issue 7
ARVO Annual Meeting Abstract  |   June 2015
Using patient-level data for meaningful cross-trial comparisons in the visual impairment due to diabetic macular edema treated with anti-VEGF agents.
Author Affiliations & Notes
  • Sobha Sivaprasad
    NIHR Biomedical Research Centre, Moorfields Eye Hospital, London, United Kingdom
    King's College Hospital, London, United Kingdom
  • Franck Fajnkuchen
    Centre Ophthalmologique d’Imagerie et de Laser, Paris, France
    Hôpital Avicenne, APHP, Bobigny, France
  • Stephane A Regnier
    Novartis Pharma AG, Basel, Switzerland
  • Jonathan Wright
    Numerus Ltd, Wokingham, United Kingdom
  • Michael Larsen
    Department of Ophthalmology, Glostrup Hospital, University of Copenhagen, Glostrup, Denmark
    National Eye Clinic, Kennedy Center, Glostrup, Denmark
  • Footnotes
    Commercial Relationships Sobha Sivaprasad, Allergan (F), Allergan (R), Bayer (F), Bayer (R), Novartis (F), Novartis (R), Roche (R); Franck Fajnkuchen, Allergan (C), Bayer (C), Novartis AG (C); Stephane Regnier, Novartis AG (E); Jonathan Wright, Novartis AG (C); Michael Larsen, Allergan (C), Allergan (F), AstraZeneca (C), GlaxoSmithKline (C), GlaxoSmithKline (F), Novartis AG (C), Novartis AG (F), Novo Nordisk (C), Roche (C), Roche (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 1731. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sobha Sivaprasad, Franck Fajnkuchen, Stephane A Regnier, Jonathan Wright, Michael Larsen; Using patient-level data for meaningful cross-trial comparisons in the visual impairment due to diabetic macular edema treated with anti-VEGF agents.. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1731.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: Produce meaningful comparisons of clinical trials of anti-vascular endothelial growth factor (VEGF) therapies in the treatment of visual impairment (VI) due to diabetic macular edema (DME).

Methods: The analysis consisted of five steps: (1) identify the baseline characteristics impacting the increase in best-corrected visual acuity (BCVA) with anti-VEGF therapies (2) create a model with RESPOND/RESTORE patient-level data to estimate the impact of key baseline characteristics on BCVA gains from baseline to month 12 (3) predict the average BCVA gain with ranibizumab 0.5 mg pro re nata (PRN) (monotherapy and ranibizumab+laser combination therapy) and laser monotherapy, assuming the same baseline characteristics as in VIVID/VISTA (4) compare the predicted gains with aflibercept bi-monthly (2q8) gains in VIVID/VISTA using a Bayesian network meta-analysis with fixed treatment effect (5) run sensitivity analyses to assess the robustness of the results.

Results: The baseline characteristics frequently associated with BCVA gains in the literature are baseline age, central retinal thickness (CRT) and BCVA. Without adjusting for those baseline variables (i.e. using raw clinical data), RESTORE/RESPOND patients on ranibizumab 0.5 mg PRN gained, on average, 6.6 letters (95% credible interval [95% CrI]: 4.5-8.7) more than those on laser monotherapy. If RESPOND/RESTORE patients were similar to those in VIVID/VISTA (in terms of age, CRT and BCVA at baseline), the model predicted 9.3 more letters (95% CrI: 6.8-11.8) for patients on ranibizumab 0.5 mg PRN than for those receiving laser monotherapy and 9.4 more letters (95% CrI: 6.8-11.9) for combination therapy patients. Those results were non-statistically different (2-sided p-value: 0.65 for ranibizumab monotherapy and 0.68 for combination therapy) compared to the BCVA gain observed for aflibercept 2q8 in VIVID/VISTA (10.0 more letters than laser, 95% CrI: 8.3-11.7). Adding baseline characteristics to the model (gender, baseline duration of diabetes, baseline HbA1c) also produced a predicted gain of 9.3 letters (95% CrI: 6.5-12.1) for ranibizumab patients over laser.

Conclusions: It is important to adjust for baseline characteristics influencing outcomes when comparing clinical trials. After doing so, the difference in letters gained between patients receiving ranibizumab and aflibercept is non-significant.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.